Drug General Information (ID: DDISH8EXLA)
Drug Name			Exenatide		Drug Info		Insulin aspart (aspart protamine)		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Hypoglycemic Agents				Antidiabetic Agents
Structure

Mechanism of Exenatide-Insulin aspart (aspart protamine) Interaction (Severity Level: Moderate)
Increased risk of hypoglycemia Click to Show/Hide Mechanism Graph
Drug Name		Exenatide				Insulin aspart (aspart protamine)
Mechanism		Hypoglycemic effects				Hypoglycemic effects
Key Mechanism Factor 1
		Factor Name		Hypoglycemia
		Factor Description		Hypoglycemia is a condition in which your blood sugar (glucose) level is below the standard range. It causes irregular or rapid heartbeat, pale skin, numbness of the lips, tongue or cheeks, and sweating.
Mechanism Description		Increased risk of hypoglycemia by the combination of Exenatide and Insulin aspart (aspart protamine)

Recommended Action
Management		When a GLP-1 receptor agonist is used as add-on therapy to basal insulin, a lower dosage of insulin may be required. Blood glucose should be monitored closely, and patients should be counseled to recognize the symptoms of hypoglycemia such as headache, dizziness, drowsiness, nervousness, confusion, tremor, hunger, weakness, perspiration, palpitation, and tachycardia. If hypoglycemia occurs, patients should initiate appropriate remedial therapy immediately and contact their physician. Patients should also be advised to take precautions to avoid hypoglycemia while driving or operating hazardous machinery. Concurrent use of GLP-1 receptor agonists with prandial insulin has not been studied and is generally not recommended.

References
1	Product Information. Adlyxin (lixisenatide). sanofi-aventis, Bridgewater, NJ.
2	Product Information. Trulicity (dulaglutide). Eli Lilly and Company, Indianapolis, IN.
3	Product Information. Ozempic (semaglutide). Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.